Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Blood Cells, Molecules & Diseases|January 1, 1995
Three new exon 10 glucose-6-phosphate dehydrogenase mutationsE Beutler, B Westwood, A Melemed, et al.Oncology|January 26, 2002
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trialM Blackstein, C L Vogel, R Ambinder, et al.Lipids|December 1, 1991
Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cellsJ P Tolins, A Melemed, D Sulciner, et al.Gynecologic Oncology|January 22, 2005
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinomaM F Kose, J Sufliarsky, S Beslija, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancerP N Münster, A Buzdar, K Dhingra, et al.Plos One|November 19, 2013
Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lungTimothy R Holzer, Angie D Fulford, Drew M Nedderman, et al.British Journal of Cancer|September 14, 2016
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumabCharles S Fuchs, Josep Tabernero, Jiří Tomášek, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III studyJ Tabernero, R R Hozak, T Yoshino, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancerRalph G Zinner, Coleman K Obasaju, David R Spigel, et al.Pageof 1